Practical asymmetric synthesis of Efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor

Journal of Organic Chemistry

Volumn 63, Issue 23, 1998, Pages 8536-8543

  Pierce, Michael E ^a   Parsons Jr , Rodney L ^a   Radesca, Lilian A ^a   Lo, Young S ^a   Silverman, Stuart ^a   Moore, James R ^a   Islam, Qamrul ^a   Choudhury, Anusuya ^a   Fortunak, Joseph M D ^a   Nguyen, Dieu ^a   Luo, Chi ^a   Morgan, Susan J ^a   Davis, Wayne P ^a   Confalone, Pat N ^a   Chen, Cheng Yi ^b   Tillyer, Richard D ^b   Frey, Lisa ^b   Tan, Lushi ^b   Xu, Feng ^b   Zhao, Dalian ^b   Thompson, Andrew S ^b   Corley, Edward G ^b   Grabowski, Edward J J ^b   Reamer, Robert ^b   Reider, Paul J ^b   more..

^a DUPONT COMPANY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLOROANILINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEAR MAGNETIC RESONANCE;

EID: 15644370082     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo981170l     Document Type: Article

References (33)

1. Romero, D. L. Ann. Rep. Med. Chem. 1994, 29, 123.
2. Tucker, T. J.; Lyle, T. A.; Wiscount, C. M.; Britcher, S. F.; Young, S. D.; Sanders, W. M.; Lumma, W. C.; Goldman, M. E.; O'Brien, J. A.; Ball, R. G.; Homnick, C. F.; Schlief, W. A.; Emini, E. A.; Huff, J. R.; Anderson, P. S. J. Med. Chem. 1994, 37, 2437.
3. Quinn, T. C. Lancet 1996, 348, 99.
4. De Clercq, E. J. Med. Chem. 1995, 38, 2491.
5. Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumma, W. C.; Lyle, T. A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll, S. S.; Pettibone, D. J.; O'Brien, J. A.; Ball, R. G.; Balani, S. K.; Lin, J. H.; Chen, I.-W.; Schleif, W. A.; Sardana, V. V.; Long, W. J.; Byrnes, V. W.; Emini, E. A. Antimicrob. Agents Chemother. 1995, 39, 2602.
6. Mayers, D.; Riddler, S.; Bach, M.; Stein, D.; Havlir, M. D.; Kahn, J.; Ruiz, N.; Labriola, D. F.; and the efavirenz clinical development team. Durable Clinical Anti-HIV-1 Activity and Tolerability for efavirenz in Combination with Indinavir (IDV) at 24 Weeks. Clinical data presented at the ICAAC meeting, Toronto, 1997, I-175.
7. Thompson, A. S.; Corley, E. G.; Huntington, M. F.; Grabowski, E. J. J. Tetrahedron Lett. 1995, 36, 8937.
8. Thompson, A.; Corley, E. G.; Hungtington, M. F.; Grabowski, E. J. J.; Remenar, J. F.; Collum, D. B. J. Am. Chem. Soc. 1998, 120, 2028.
9. A synthesis of racemic efavirenz, followed by resolution, has been reported. Radesca, L. A.; Lo, Y. S.; Moore, J. R.; Pierce, M. E. Synth. Commun. 1997, 27, 4373.
10. (a) Mukaiyama, T.; Suzuki, K.; Soai, K.; Sato, T. Chem. Lett. 1979, 447.
11. (b) Mukaiyama, T.; Suzuki, K. Chem. Lett. 1980, 255.
12. (c) Niwa, S.; Soai, K. J. Chem. Soc., Perkin Trans. 1 1990, 937-943.
13. (d) Tombo, G. M. R.; Didier, E.; Loubinoux, B. Synlett 1990, 547-548.
14. (e) Corey, E. J.; Cimprich, K. A. J. Am. Chem. Soc. 1994, 116, 3151-3152.
15. (f) Huffman, M. A.; Nobuyoshi, Y.; DeCamp, A. D.; Grabowski, E. J. J. J. Org. Chem. 1995, 60, 1590.
16. Fuhrer, W.; Gschwend, H. W. J. Org. Chem. 1979, 44, 1133,.
17. Bates, R. B.; Kroposki, L. M.; Potter, D. E. J. Org. Chem. 1972, 37, 560.
18. A similar acid-catalyzed benzylation of amides was reported. Henneuse, C.; Boxus, T.; Tesolin, L.; Pantano, G.; Marchand-Brynaert, J. Synthesis 1996, 495.
19. Emert, J.; Goldenberg, M.; Chiu, G. L.; Valeri, A. J. Org. Chem. 1977, 42, 2012.
20. (a) Soai, K.; Yokoyama, S.; Hayasaka, T. J. Org. Chem. 1991, 56, 4264.
21. 3 as a base was reported to give pyrrolidyl derivatives in moderate yields. Moffett, R. B. J. Org. Chem. 1949, 14, 2.
22. This simple and efficient alkylation procedure has now been used to prepare a wide variety of N,N-cycloalkyl derivatives of amino alcohols.
23. Thompson, A.; Corley, E. G. Org. Synth. 1997, in press.
24. (a) Schoberth, W.; Hanack, M. Synthesis 1972, 703.
25. (b) Scott, L. T.; Cooney, M. J.; Otte, C.; Puls, C.; Haumann, T.; Boese, R.; Carroll, P. J.; Smith, A. B., III; de Meijere, A. J. Am. Chem. Soc. 1994, 116, 10275.
26. (c) Lambert, J. B.; Papay, J. J.; Mark, H. W. J. Org. Chem. 1975, 40, 633.
27. Bolm, C.; Bienewald, F.; Seger, A. Angew. Chem., Int. Ed. Engl. 1996, 35, 1657.
28. The reaction may alternately be quenched into 2 N aqueous HCl without loss of 2a into the aqueous phase. Aqueous HCl may also be used interchangeably with citric acid in purifying and recycling the ligand 5b.
29. The product 2a readily upgrades in optical purity upon crystallization.
30. The less expensive quinone chloranil was also used for the deprotection step. However, the initial oxidation of 2a to give the cyclic aminals 13a/13b is not as efficient as the reaction involving DDQ, and aminals 13a/13b required purification (by crystallization) prior to conversion into the amino alcohol 2b. The isolated yield of 2b from this two-step procedure was 75-80%.
31. The structure of 13b was determined by comprehensive heteronuclear NOE (HOESY) experiments. Yu, C.; Levy, G. C. J. Am. Chem. Soc. 1984, 106, 6533.
32. Newman, M. S., Khanna, V. K. Org. Prep. Proced. Int. 1986, 17(6), 422-423.
33. 3 ensures pH < 8.5 and complete formation of the carbamate 14b before addition of KOH to effect ring closure.